SEC Form 4 · accession 0001104659-15-049022

CATABASIS PHARMACEUTICALS INC · CATB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Nicholas Galakatos

Director · 10% Owner

Period of report

Jun 30, 2015

Accepted (ET)

Jun 30, 2015 · 6:47 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001454789

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2,F3	Jun 30, 2015	C	1,618,676	—	A	1,618,676	I	See Footnotes
Common Stock^F1,F2,F3	Jun 30, 2015	C	757,117	—	A	2,375,793	I	See Footnotes
Common Stock^F2,F3	Jun 30, 2015	P	376,695	$12.00	A	2,752,488	I	See Footnotes

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Preferred Stock^F2,F3,F1	—	Jun 30, 2015	C	20,800,000	D	—	—	Common Stock	1,618,676	0	I
Series B Preferred Stock^F2,F3,F1	—	Jun 30, 2015	C	9,728,971	D	—	—	Common Stock	757,117	0	I
Stock Option (right to buy)^F4	$12.21	Jun 30, 2015	A	11,094	A	—	Jun 29, 2025	Common Stock	11,094	11,094	D

Explanation of responses

F1The Series A and Series B Preferred Stock converted into Common Stock on a 1-for-12.85 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
F2These shares are owned directly by Clarus Lifesciences II, L.P. ("Clarus"). Clarus Ventures II GP, L.P. (the "GPLP"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLP disclaims beneficial ownership of all shares held of record by Clarus in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus.
F3The GPLLC disclaims beneficial ownership of all shares held of record by Clarus in which it does not have an actual pecuniary interest. Each of Dr. Galakatos, Denis Henner, Robert Liptak, Nicholas Simon, Michael Steinmetz and Kurt Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Dr. Galakatos disclaims beneficial ownership of all shares held of record by Clarus in which he does not have an actual pecuniary interest.
F4This option was granted on June 30, 2015 and vests over three years, with one-third of the shares vesting on each anniversary of the grant date until the third anniversary of the grant date.